TREATMENT OF HEART FAILURE IN HUMANS Russian patent published in 2024 - IPC A61K31/713 C12N15/00 A61P9/00 

FIELD: medicine; pharmaceutical industry.

SUBSTANCE: use of an oligonucleotide containing a sequence of formula III:

5'-dA*+T*dG*+G*dC*+T*dG*+T*dA*+G*dA*dC*dT*dG*+T*+T 3', where dA represents 2'-deoxyadenosine, dG is 2'-deoxyguanosine, dC is 2'-deoxycytidine, and T is thymidine, where +T is a LNA-T building block, and +G is a LNA-G building block, and where * represents is a phosphorothioate linkage, in the prevention or treatment of a cardiac disorder in a human, wherein the cardiac disorder is selected from (i) acute or subacute heart failure, (ii) chronic and/or worsening chronic heart failure, (iii) stable heart failure, (iv) less advanced heart failure or advanced heart failure, (v) NYHA stage I and/or II heart failure, NYHA stage I, II and/or III or NYHA stage III and/or IV, and (vi) left-sided or right-sided heart failure; use of an oligonucleotide containing a sequence of formula III:

5'-dA*+T*dG*+G*dC*+T*dG*+T*dA*+G*dA*dC*dT*dG*+T*+T-3', where dA represents 2 '-deoxyadenosine, dG is 2'-deoxyguanosine, dC is 2'-deoxycytidine, and T is thymidine, where +T is the LNA-T building block, and +G is the LNA-G building block, and where * is a thiophosphate bond, in the prevention or treatment of fibrotic disorder; a method of monitoring therapy with an oligonucleotide that is the target of said nucleotide, comprising determining the amount and/or activity of miR-132 in a sample obtained from a subject to whom the oligonucleotide was administered, the determination being carried out one or more times during the course of therapy; use of a kit containing: a primer that binds to DNA encoding miR-132 or DNA that is complementary to the specified, a primer that binds to DNA encoding miR-39 or DNA that is complementary to the specified, optional positive control hsa-miR-132, and optionally a positive control for miR-39, in the said method of monitoring therapy.

EFFECT: use of a group of inventions ensures the prevention and treatment of cardiac and/or fibrotic disorders.

31 cl, 36 dwg, 16 ex